Enrollment complete in 2 Phase 2 trials testing hepatitis B treatment
Enrollment is complete in two Phase 2 clinical trials testing Ausperbio’s AHB-137 in people with chronic hepatitis B, the company said. That “positions us…
Hepatitis
Program improves hepatitis C treatment access for new moms
A simple shift in where new mothers receive care is helping the fight against hepatitis C. By bringing infectious disease specialists to a mother’s…
FDA OKs clinical trials to test cell therapy for chronic hepatitis B
The U.S. Food and Drug Administration (FDA) has given Lion TCR the green light to start Phase 1b/2 clinical trials testing LioCyx-M004, the clinical-stage…
Phase 3 Trial of brelovitug for hepatitis D enrolls 1st patient
The first participant has been enrolled in a Phase 3 clinical trial testing Bluejay Therapeutics’ investigational therapy brelovitug against bulevirtide in adults with chronic…
Gene-editing approach may one day cure chronic hepatitis B: Study
A gene-editing therapy designed to specifically inactivate a hidden genetic blueprint of the hepatitis B virus (HBV) — the cause of hepatitis B —…
Canada clears fast fingerstick test for hepatitis C
A one-hour point-of-care test for hepatitis C has been cleared for use in Canada, which could help accelerate diagnosis and monitor how people with…
Treatment of hepatitis B needs global overhaul, per WHO study
Current approaches to hepatitis B care across the globe are failing to adequately connect patients with treatment, and also to retain them for long-term…
Dosing begins in Phase 2 trial of ALG-000184 for hepatitis B
The first participant has been dosed in a Phase 2 clinical trial testing Aligos Therapeutics’ oral treatment candidate ALG-000184 in people chronically infected with…
Fatty liver disease linked to projected rise in liver cancer
The proportion of cases of hepatocellular carcinoma (HCC) attributable to fatty liver disease is set to rise in the next 25 years, with obesity…
3 trials of Vir’s hepatitis D combo treatment now up and running
The first participant has been enrolled in ECLIPSE 3, a Phase 2b clinical trial testing Vir Biotechnology’s combination treatment of tobevibart and elebsiran against…
Recent Posts
- Nebokitug reduces immune cell activity that drives PSC: Data
- New biomarkers may help detect pregnancy-linked liver complication
- Access to food is a survival tactic when your liver needs nutrition
- Belapectin may help reduce liver scarring in those with severe MASH
- Parents and son are all on a path of discovery with Alagille syndrome